Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 monotherapy as neoadjuvant/adjuvant therapy for resectable MSI-H/dMMR colon cancer
CTR20260498Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in colon adenocarcinoma, sponsored by Akeso, Inc.. Started Mar 2026; status: active.
02
Drugs
cadonilimab
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on CTR20260498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260498.